Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in Pediatric Lower Limb Spasticity
NCT01603641Phase 3Completed
- Sponsor
- Allergan
- Start
- Nov 2012
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of onabotulinumtoxinA in Spasticity, sponsored by Allergan. Primary endpoint: Percentage of Participants With at Least One Treatment-emergent Adverse Event up to 60 weeks. Started Nov 2012; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT01603641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01603641.